These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 6005619)
1. [Porphyria cutanea tarda with hypersideremia: effectiveness of desferrioxamine (Desferal)]. Beurey J; Weber M; Montet Y; Jeandidier P; Barbier JM Arch Belg Dermatol Syphiligr; 1966; 22(4):235-41. PubMed ID: 6005619 [No Abstract] [Full Text] [Related]
2. [Treatment of porphyria cutanea tarda with desferrioxamine (Desferal)]. Amerio PL; Garcovich A; Ormea F Minerva Dermatol; 1967 Dec; 42(12):627-9. PubMed ID: 5622841 [No Abstract] [Full Text] [Related]
3. [Experiences with iron elimination therapy in porphyria cutanea tarda]. Haneke E; Schwartze G Z Gesamte Inn Med; 1971 Nov; 26(22):710-6. PubMed ID: 5141034 [No Abstract] [Full Text] [Related]
4. A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients. Marchesi L; Di Padova C; Cainelli T; Reseghetti A; Di Padova F; Rovagnati P; Cantoni L Photodermatol; 1984 Dec; 1(6):286-92. PubMed ID: 6398430 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of porphyria cutanea tarda by iron chelators (EDTA, Desferral)]. Thivolet J; Bondet P; Perrot H; Moene Y Lyon Med; 1967 Aug; 218(32):225-30. PubMed ID: 4975716 [No Abstract] [Full Text] [Related]
6. [Porphyria cutanea tarda: study of the changes in porphyrin metabolism during desferrioxamine therapy]. Mazza U; Bianco G; Fiorina L; Prato V Boll Soc Ital Biol Sper; 1965 Jan; 41(1):2-4. PubMed ID: 5875798 [No Abstract] [Full Text] [Related]
7. [Quantitative determination of urinary porphyrins using Rimington's and Sveinsson's technic and experience in the therapy of porphyria cutanea tarda using Desferal CIBA]. Votruba M; Nozicková M; Pazderka J Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1969; 12(3):313-9. PubMed ID: 5265982 [No Abstract] [Full Text] [Related]
8. Desferrioxamine in the treatment of porphyria cutanea tarda: ineffectiveness of intramuscular administration. Muñoz JJ; Garcia-Cabezas J; Martinez-Verano J; Perez-Oteyza C; Enriquez de Salamanca R J Dermatol; 1990 May; 17(5):329-31. PubMed ID: 2380437 [TBL] [Abstract][Full Text] [Related]
9. [Clinical and biological effects of chelating agents in porphyria cutanea tarda]. Thivolet J; Perrot H; Mallein R; Sabater P Presse Med (1893); 1968 Feb; 76(8):367-70. PubMed ID: 4967022 [No Abstract] [Full Text] [Related]
10. Iron metabolism and its responses to allopurinol treatment in porphyria cutanea tarda. Burger T; Horváth T; Jávor T Acta Med Acad Sci Hung; 1978; 35(2):115-27. PubMed ID: 742338 [TBL] [Abstract][Full Text] [Related]
11. [Catamnestic studies in porphyria cutanea tarda with special reference to therapy]. Barth J; Petter O Z Gesamte Inn Med; 1971 Jan; 26(2):66-74. PubMed ID: 5560767 [No Abstract] [Full Text] [Related]
12. Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. Praga M; Enriquez de Salamanca R; Andres A; Nieto J; Oliet A; Perpiña J; Morales JM N Engl J Med; 1987 Feb; 316(9):547-8. PubMed ID: 3808000 [No Abstract] [Full Text] [Related]
13. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Rocchi E; Gibertini P; Cassanelli M; Pietrangelo A; Borghi A; Pantaleoni M; Jensen J; Ventura E Br J Dermatol; 1986 May; 114(5):621-9. PubMed ID: 3718853 [TBL] [Abstract][Full Text] [Related]